List view / Grid view
Medical screening is a strategy used to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms.
CRISPR screening utilises the power and precision of CRISPR-Cas9 gene editing to reveal and validate novel drug targets or to study the underlying causes of disease.
Potential drugs not only need to bind to their targets, they also need to remain bound for a specific amount of time in order to work efficiently.
In a time when rapid screening and fast-paced drug development are necessary for fighting illness and disease, having a robust supply of high-quality, fit-for-purpose consumables is critical.
Included in this in-depth focus are articles on how high-throughput screening can be used to identify lead compounds, using chemoinformatics as a map to guide drug discovery and a novel in vitro model to screen potential treatments for non-alcoholic fatty liver disease (NAFLD).
Learn practical tips from eight Principal Investigators about how to start your own lab.
Collaborative research has revealed two hallmarks of COVID-19 infection associated with more severe symptoms that can be identified by a blood test.
Researchers are utilising computers to aid in their investigations into a COVID-19 treatment. Here, we highlight three studies using simulations, calculations and AI to identify a drug to combat the coronavirus.
Learn how you could use high-content analysis for functional & phenotypic assays in your infectious disease research or drug discovery.
Bioassays and thin-layer chromatography has been used by scientists to analyse molecules in plant extracts as a fast and cost-effective method for identifying new drug compounds.
7 May 2020 | By PerkinElmer
High-throughput screening (HTS) cascades have evolved to ensure that high quality hits can be identified from large screening collections.
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.
A series of three new assays to screen for drug compounds or proteins that combat the COVID-19 coronavirus has been developed.
Bringing together protein science, drug discovery experience and innovative technology, a new collaboration aims to identify novel drug targets for COVID-19.
A new study has revealed that less than 10 percent of respiratory and intestinal cells are susceptible to SARS-CoV-2 infection and expression of ACE2 receptors is driven by the body's immune response.
The developers of a novel method to create immunological assay probes for screening T cells has leveraged their new protocol against COVID-19.
